Dear Users,
In order to provide more trading options on the VOOX futures platform and enhance the user trading experience, VOOX will launch PNUTUSDT, NEIROUSDT, and MORPHOUSDT perpetual contracts on December 11, 2024.
Please refer to the table below for more details about the PNUTUSDT Perpetual Futures:
USDⓈ-M Perpetual Contract |
Details |
Launch Time |
December 12, 2024, 16:00 (UTC+8) |
Underlying Asset |
PNUT |
Settlement Asset |
USDT |
Minimum Price Movement |
0.00001 |
Maximum Leverage |
75 |
Funding Fee Settlement Frequency |
Every 8 hours at 00:00, 04:00, 12:00, and 20:00 (UTC+8) |
Trading Hours |
24*7 |
Please refer to the table below for more details about the NEIROUSDT Perpetual Futures:
USDⓈ-M Perpetual Contract |
Details |
Launch Time |
December 12, 2024, 16:00 (UTC+8) |
Underlying Asset |
NEIRO |
Settlement Asset |
USDT |
Minimum Price Movement |
0.0000001 |
Maximum Leverage |
75 |
Funding Fee Settlement Frequency |
Every 8 hours at 00:00, 04:00, 12:00, and 20:00 (UTC+8) |
Trading Hours |
24*7 |
Please refer to the table below for more details about the MORPHOUSDT Perpetual Futures:
USDⓈ-M Perpetual Contract |
Details |
Launch Time |
December 12, 2024, 16:00 (UTC+8) |
Underlying Asset |
TON |
Settlement Asset |
USDT |
Minimum Price Movement |
0.0001 |
Maximum Leverage |
75 |
Funding Fee Settlement Frequency |
Every 8 hours at 00:00, 04:00, 12:00, and 20:00 (UTC+8) |
Trading Hours |
24*7 |
- According to market risk conditions, VOOX may adjust the above futures parameters, including adjustments to funding rates, minimum tick sizes, maximum leverage, initial margin, maintenance margin, and other important parameters;
- Futures and spot currencies are not related. The futures launched on VOOX do not guarantee that they will be available on VOOX's spot market.
[Risk Warning] The crypto market and events carry inherent risks, and digital investment decisions should be made with caution. We advise users to carefully assess their own investment capability and risk tolerance.
VOOX Team
December 11, 2024
Comments
0 comments
Article is closed for comments.